Lanadelumab for Treatment of COVID-19 Disease

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04422509

Acronym

COVID_LAN

Enrollment

Registered

2020-06-09

Start date

2020-10-30

Completion date

2021-04-30

Last updated

2021-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

Interventions

BIOLOGICALlanadelumab

single dose, or two doses administered iv

OTHERregular care

no lanadelumab administration, treated according to regular care

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

controls will get standard of care and historical controls will be matched to the patients included

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient is SARS-COV2 positive (PCR) * Without oxygen a saturation below 90% * At least 3L/min oxygen dependent * Patient is 16 years and older

Exclusion criteria

* Has previously participated in this study * Acute myocardial or cerebral ischemic event at time of enrolment * Receiving ACE or ARB inhibitor or comparable drugs that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent * A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal * Patient is known hypersensitive to full human monoclonal antibodies * Patient is pregnant or breast feeding

Design outcomes

Primary

Measure	Time frame	Description
oxygen	2 weeks	oxygen use in L/min

Secondary

Measure	Time frame	Description
adverse events	2 weeks	adverse events after lanadelumab administration

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026